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Insidious pathogen-mimicking properties 
of nanoparticles in triggering the lectin pathway 
of the complement system
Abstract: The lectin pathway of the complement system is 
an integral component of the innate immune system rec-
ognizing pathogens through patterns of sugar moieties dis-
played on their surfaces and neutralizing them through an 
antibody-independent reaction cascade. Many engineered 
nanoparticles incite complement through the lectin path-
way, but these nanoparticles inherently do not express 
surface-exposed sugars. However, the projected polymeric 
surface architecture of nanoparticles may transiently resem-
ble structural motifs of peptidoglycan constituents of patho-
gens and trigger the lectin pathway. We discuss these issues 
in relation to nanomedicine design and immune safety.
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Nanoparticles and the complement 
system
Many functional particles (e.g., iron oxide nanocrystals, 
gold nanoparticles, carbon nanotubes, graphene) and 
drug carriers (e.g., liposomes, polymeric nanospheres, 
oil-in-water emulsions, polymeric micelles) exhibit an 
array of ‘pathogen-mimicking’ properties, which arises 
from a combination of their nanoscale size and aspect 
ratio, morphology and surface display of repetitive 
epitopes (e.g., clusters of functional groups, surface pro-
jected polymers), making them susceptible for intercep-
tion by the body’s defences (1). The complement system is 
a key component of the innate immunity, which can be trig-
gered by a wide repertoire of invading particles (including 
pathogens) (2). Accordingly, the complement system pro-
vides critical immunoprotective and immunoregulatory 
functions comprising opsonization, lytic and inflamma-
tory processes (e.g., chemotaxis and leukocyte activation) 
(2). There are three established pathways of complement 
activation: classical, lectin and alternative pathways (2). 
Each pathway is triggered differently, but they converge to 
generate the same set of effector molecules (2, 3).
Complement activation and fixation has been a 
central point for efficient clearance of nanoparticles and 
drug carriers by phagocytic cells (4, 5). On the other hand, 
inadvertent complement activation may initiate adverse 
reactions and this has been noted following infusion of 
many therapeutic agents including antibody, polymeric, 
micellar- and particulate-based formulations into human 
subjects (6–8). The exact role and contribution of the com-
plement system in infusion-related reactions is not clear, 
but liberation of complement bioactive products (e.g., C3a, 
C5a and C5b-9) can potentially modulate the function of 
a variety of immune cells (e.g., macrophages, monocytes, 
polymorphonuclear cells, platelets, mast cells) and vas-
cular endothelial cells either directly or in cross-talk with 
pattern-recognition receptors (e.g., Toll-like receptors 
2, 4 and 9) to account for some of the observed adverse 
events (6, 7). Furthermore, complement activation is also 
of serious concern for successful development of intrave-
nous anti-cancer nanomedicine initiatives (9, 10). Indeed, 
recent studies have indicated that intratumoral accumula-
tion of complement activating long-circulating nanopar-
ticles in immunocompetent mice can accelerate tumor 
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growth through C5a liberation  (9), presumably through 
recruitment of regulatory T cells (resulting in deregulation 
or suppression of CD8+ cytotoxic T cell activity), immuno-
suppressive monocytes and alternatively activated mac-
rophages into malignant tumors as well as increasing 
tumor angiogenesis (9–11). Therefore, understanding of 
nanomaterial properties that incite complement is a pre-
requisite for design and engineering of immunologically 
safer nanomedicine and biomedical devices.
The interaction between particulate matters and the 
complement system is complex and regulated by inter-
related factors comprising morphology, dimension, chem-
ical make up and surface characteristics (3). The majority 
of complement activation studies with medically relevant 
nanoparticles have been predominantly qualitative with 
limited focus on mechanistic aspects (1, 3). In case of 
the latter, attention has been mostly towards the classi-
cal and alternative pathways (3). Compelling evidence 
now suggest that many such nanoparticles insidiously 
incite complement through the lectin pathway, which 
involve carbohydrate recognition, but these nanoparticles 
natively do not express surface-exposed sugars (12–21).
The lectin pathway
In humans, five pattern recognition molecules are capable 
of initiating the lectin pathway (22, 23). These include 
mannose-binding lectin (MBL), ficolins of M, L and H 
classes, and collectin 11 (CL11 or CL-K1) all in association 
with a complex set of serine protease zymogens. To date, 
three serine proteases, namely MBL-associated serine pro-
tease (MASP) 1, 2 and 3 have been identified (22). In addi-
tion, two non-enzymatic fragments of the MASPs (MAp44 
and MAp19) have been found in the recognition complexes 
(22). MBL binds carbohydrates with 3- and 4-hydroxyl 
groups in the pyranose ring (d-mannose and N-acetyl-
d-glucosamine, GlcNAc) in a calcium-dependent manner 
(22). Serum L- and H-ficolin has a common binding speci-
ficity for GlcNAc. The M-ficolin is not a serum protein, 
but its mRNA is found in leukocytes and lung (22). CL11 
has preference for L-fucose and d-mannose and binding 
is calcium-dependent, which resembles the specificity of 
mouse MBL-A (23). Binding of the lectin pathway recog-
nition molecules to the corresponding surface-exposed 
carbohydrate ligands activates MASPs, although the 
exact molecular details are still poorly understood (22, 
24). Typically, MASP2 cleaves the fourth and the second 
complement proteins (C4 and C2, respectively) to form 
the C3 convertase C4bC2a (22). In the absence of MASP2, 
the lectin pathway is not functional as confirmed in both 
MASP2-depleted human serum and MASP2 knockout 
mouse (25, 26). A recent study (24), however, indicated 
that MASP2 activation strictly depends on MASP1, and 
inhibition of MASP1 prevents activation of MASP2. Fur-
thermore, MASP1 was suggested to produce 60% of C2a 
responsible for C3 convertase formation (24). Accordingly, 
a new model of lectin pathway activation proposes that 
MASP1 when activated cleaves zymogen MASP2, where 
the active MASP2 then cleaves C4 and the associated C4b 
binds C2, which is then cleaved primarily by MASP1 and to 
lesser extent by MASP2 thus forming the C4bC2a complex 
(24). MASP1 is also able to cleave C3 directly, which results 
in activation of the alternative pathway (27). Others, based 
on a knockout mouse model, have also proposed a role 
for MASP1 and MASP3 in directly activating the alterna-
tive pathway factor D as well as limited factor B cleavage 
by MASP3 (28–30). However, there are ongoing debates on 
these findings (31, 32).
Examples of nanoparticle-mediated 
activation of lectin pathway
Nanoparticle surface camouflaging with materials such 
as poly(ethylene glycol)s, PEGs, and block copolymers of 
poloxamer and poloxamine series has long been shown 
to combat macrophage recognition and confer longevity 
in the blood (1, 33, 34). Although long believed that such 
strategies could suppress opsonization events in the blood 
(33, 34), recent studies have demonstrated that some of 
these engineered entities can, indeed, incite complement 
and depending on surface polymer configuration com-
plement activation may proceed exclusively through the 
lectin pathway (12, 13, 17–19, 21). For example, alteration 
of poloxamine 908 copolymer architecture on polystyrene 
nanospheres of 220 nm in size from a flat to mushroom-
brush configuration switched complement activation 
from the C1q-dependent classical pathway to a lectin 
pathway in human serum (12). This copolymer has repeti-
tive recognition patterns of relative polarity and hydro-
phobicity, where the patterns may change with changes 
in surface density of the copolymer. Consequently, this 
may create new binding sites for complement recognition 
and shifts complement activation pathway from classical 
to lectin mode. Indeed, one intriguing aspect of PEG and 
block copolymers of poloxamer and poloxamine series is 
structural similarities between their terminal region and 
d-mannose/GlcNAc (Figure 1). In this respect, the surface 
projected poly(ethylene oxide) chains of the poloxamine 
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Figure 1: Structural similarities between d-mannose, N-acetyl-d-glucosamine and selected polymers used in nanoparticle engineer-
ing. Compare sequences numbered 1–4 between the sugars and polymers, which can be repeated in different ways on both sugars. The 
arrow indicates the MBL binding site (the equatorial OH groups) in d-mannose (arrow head). The binding sites for ficolins and collectin 11, 
however, remain unknown. PEO, polyethylene oxide; PPO, polypropylene oxide. The structure of poloxamines is not shown, but polox-
amines are star-shaped copolymers comprising of four POP chains joined by a central ethylene diamine bridge, where each POP block is 
flanked at the other end by a POE chain.
908 in close proximity (as in mushroom-brush con-
figuration) may form dynamic ‘pathogen-mimicking’ 
clusters transiently resembling structural motifs of the 
d- mannose/GlcNAc, which serves as a platform for MBL/
ficolin/CL11 docking (Figure 2). Accordingly, it is not sur-
prising to see that block copolymers in different forms 
(e.g., micelles, gels) also trigger lectin pathway in a size- 
and shape-independent manner (14).
Similar observations have been reported with carbon 
nanotubes coated with PEG-conjugated molecules or 
covalently functionalized with PEG, where gross surface 
polymer architectural changes not only triggered lectin 
pathway, but further modulated the mode of lectin 
pathway activation through binding of different lectin 
pathway initiating molecules (e.g., MBL vs. L-ficolin) (13).
Non-specific adsorption of heavily glycosylated 
plasma proteins such as apolipoprotein B-100 and certain 
classes of antibodies to surface engineered nanoparticles 
may further contribute to lectin pathway activation (12, 14, 
34). On binding and conformational transformation, the 
glycosylated modules of these proteins may act as tem-
plate for binding of lectin pathway initiators.
Dextran-coated super paramagnetic iron oxide nano-
particles also incite complement through lectin pathway 
Figure 2: Possible mechanisms of nanoparticle-mediated activation 
of the complement lectin pathway. The right segment is a schematic 
representation of a polymer-coated nanoparticle. The dynam-
ics of the terminal regions of surface projected polymers (e.g., 
 poloxamers and poloxamines) in close proximity may transiently 
resemble structural motifs of N-acetyl-d-glucosamine/d-mannose 
recognizable by lectin pathway initiators (e.g., MBL, L-ficolin). See 
Figure 1 for polymer structures.
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(21). In human sera, activation was MBL-dependent as well 
as proceeding directly through the alternative pathway. In 
mouse sera, activation was MBL-A/C dependent, but alter-
native pathway contributed via the amplification loop 
only (21). These observations highlight important differ-
ences and similarities in nanoparticle-mediated comple-
ment activation between humans and mice. Accordingly, 
complement activation and related adverse events studies 
in animals may not necessarily translate into a human 
system (10, 21).
Outlook
Evolution has afforded complement system a powerful 
tool to combat pathogens through lectin pattern recogni-
tion. It is not surprising to see that man-made materials 
such as various polymers [e.g., PEG, poloxamers, polxam-
ines, poly(caprolactone), poly(glycolyic acid), poly(lactic 
acid), poly(lactide-co-glycolide), polyoxazoline, chitosan] 
and drug delivery systems based on such polymers trigger 
lectin pathway. Indeed, many such entities share structural 
motifs with peptidoglycan constituents of the pathogens 
that incite complement through MBL, ficolin and collectin 
11 binding, and therefore needs revisiting. For example, 
chitosan is composed of repeating units of d-glucosamine, 
together with residual GlcNAc units. A repertoire of glyco-
sylated plasma proteins may further aid lectin pathway 
activation on nanoparticle binding and conformational 
changes and also warrants clarification (34). Protein finger-
printing and mass spectrometry studies, however, reveal 
little in terms of surface-dependent and fluid-phase com-
plement cascade and the precise role of lectin pathway 
initiators in nanoparticle-mediated complement activation 
(35, 36), where qualitative analysis could be misleading 
(1). Future studies should examine nanoparticle-mediated 
lectin pathway activation of the human complement system 
more carefully through integrated approaches and ‘struc-
ture-activity’ mapping, which may lead to identification of 
structural motifs and geometrical arrangements that dock 
lectin pathway initiators. Collectively, these approaches 
may initiate better approaches for safer nanoparticle design 
and engineering (an ‘immune safe-by-redesign’ concept). 
Indeed, a recent study demonstrated that MBL-binding 
kinetics are critically dependent on structural characteris-
tics on the nanometer scale, including the dimensions of 
polyvalent MBL oligomers as well as the mode of ligand 
presentation on surfaces (37). Future developments in 
microstamping may further aid mechanistic understanding 
of spatial and architectural arrangements of immobilized 
polymers in controlling the binding kinetics of lectin 
pathway initiators. Through such studies and computa-
tional analysis it may be possible to simulate time-depend-
ent nanoparticle surface changes in vivo (e.g., in the blood 
or on nanoparticle extravasation to interstitial spaces) that 
may subsequently shift complement activation from one 
pathway to another, thereby initiating delayed reactions. 
Finally, complement activation as whole seems to play an 
important role in nanomedicine-mediated infusion-related 
reactions and progression of cancer, but the exact contribu-
tion of the lectin pathway needs to be mapped out. Accord-
ingly, we should be cautious in extrapolating the outcomes 
of animal studies to human safety pertaining intravenous 
nanomedicines and nanopharmaceuticals, since there are 
differences in complement activation processes between 
humans and other species and particularly in relation to 
lectin pathway activation.
Acknowledgments: SMM acknowledges financial support 
by the Danish Agency for Science, Technology and Inno-
vation, reference 09-065736 (Det Strategiske Forskning-
sråd) and the European Community’s Seventh Framework 
Programme (FP7-NMP-2012-Large-6) under grant agree-
ment No. 310337-2 CosmoPHOS-nano.
References
1. Moghimi SM, Hunter AC, Andresen TL. Factors controlling nano-
particle pharmacokinetics: an integrated approach and perspec-
tive. Annu Rev Pharmacol Toxicol 2012;52:481–503.
2. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement – 
a key system for immune surveillance and homeostasis. Nat 
Immunol 2010;11:785–97.
3. Moghimi SM, Andersen A, Ahmadvand D, Wibroe PP, Andresen TL, 
Hunter AC. Material properties in complement activation. Adv 
Drug Deliv Rev 2011;63:1000–7.
4. Moghimi SM, Parhamifar L, Ahmadvand D, Wibroe PP, Andresen TL, 
Farhangrazi ZS, et al. Particulate systems for targeting of 
macrophages: basic and therapeutic concepts. J Innate Immun 
2012;4:509–28.
5. Moghimi SM, Farhangrazi ZS. Nanoparticle in medicine: 
nanoparticle engineering for macrophage targeting and 
nanoparticles that avoid macrophage recognition. In: Boraschi D, 
Duschl A, editors. Nanoparticles and the immune system. Safety 
and effects. San Diego: Elsevier, 2014:77–89.
6. Moghimi SM, Wibroe PP, Helvig SY, Farhangrazi ZS, Hunter AC. 
Genomic perspectives in inter-individual adverse responses fol-
lowing nanomedicine administration: the way forward. Adv Drug 
Deliv Rev 2012;64:1385–93.
7. Moghimi SM, Farhangrazi ZS. Nanomedicine and complement 
paradigm. Nanomedicine: Nanotechnol Biol Med 2013;9:458–60.
8. Szebeni J. Complement activation-related pseudoallergy: a stress 
reaction in blood triggered by nanomedicines and biological. Mol 
Immunol 2014;61:163–73.
Brought to you by | University of Durham
Authenticated
Download Date | 6/21/16 5:31 PM
Moghimi et al.: Insidious pathogen-mimicking properties of nanoparticles      267
9. Moghimi SM. Cancer nanomedicines and the complement 
system activation paradigm: anaphylaxis and tumour growth. 
J Control Rel 2014;190:556–62.
10. Moghimi SM, Farhangrazi ZS. Just so stories: random acts of 
anti-cancer nanomedicine performance. Nanomedicine: Nano-
technol Biol Med 2014;10:1661–66.
11. Sabnani MK, Rajan R, Rowland B, Mavinkurve V, Wood LM, 
Gabizon AA, et al. Liposome promotion of tumor growth is 
associated with angiogenesis and inhibition of antitumor immune 
responses. Nanomedicine: Nanotechnol Biol Med 2015;11:259–62.
12. Hamad I, Al-Hanbali O, Hunter AC, Rutt KJ, Andresen TL, 
Moghimi SM. Distinct polymer architecture mediates switch-
ing of complement activation pathways at nanosphere-serum 
interface: implications for stealth nanoparticles engineering. 
ACS Nano 2010;4:6629–38.
13. Andersen AJ, Robinson JT, Dai H, Hunter AC, Andresen TL, 
Moghimi SM. Single-walled carbon nanotubes surface control of 
complement sensing and activation. ACS Nano 2013;7:1108–19.
14. Hamad I, Hunter AC, Moghimi SM. Complement activation 
by Pluronic 127 gel and micelles: suppression of copolymer-
mediated complement activation by elevated serum levels 
of HDL, LDL, and apolipoproteins A-I and B-100. J Control Rel 
2013;170:167–74.
15. Andersen AJ, Windschiegl B, Ilbasmis-Tamer S, Degim IT, 
Hunter AC, Andresen TL, et al. Complement activation by PEG-
functionalized MWCNTs is independent of PEG molecular mass 
and surface density. Nanomedicine: Nanotechnol Biol Med 
2013;9:469–73.
16. Wibroe PP, Moghimi SM. Complement sensing of nanoparticles 
and nanomedicines. In: Hepel M, Zhong CJ, editors. Functional 
nanoparticles for bioanalysis, nanomedicine and bioelectronic 
devices, ACS Symposium Series, American Chemical Society, 
2012;2:365–82.
17. Moghimi SM, Andersen AJ, Hashemi SH, Lettiero B, Ahmadvand D, 
Hunter AC, et al. Complement activation cascade triggered by 
PEG-PL engineered nanomedicines and carbon nanotubes: the 
challenges ahead. J Control Rel 2010;146:175–81.
18. Moghimi SM, Hunter AC. Complement monitoring of carbon 
nanotubes. Nat Nanotechnol 2010;5:382.
19. Hamad I, Hunter AC, Rutt KJ, Liu Z, Dai H, Moghimi SM. Comple-
ment activation by PEGylated single-walled carbon nanotubes 
is independent of C1q and alternative pathway turnover. Mol 
Immunol 2008;45:3797–803.
20. Hamad I, Hunter AC, Szebeni J, Moghimi SM. Poly(ethylene 
glycol)s generate complement activation products in human 
serum through increased alternative pathway turnover and a 
MASP-2-dependent process. Mol Immunol 2008;46:225–32.
21. Banda NK, Mehta G, Chao Y, Wang G, Inturi S, Fossati-Jimak L, 
et al. Mechanisms of complement activation by superparama-
gentic dextran iron oxide (SPIO) nanoworms in mouse versus 
human sera. Particle Fibre Toxicol 2014;11:64.
22. Fujita T. Evolution of the lectin-complement pathway and its 
role in innate immunity. Nat Rev Immunol 2002;2:346–53.
23. Hansen S, Selman L, Palaniyar N, Ziegler K, Brandt J, Kliem A, 
et al. Collectin 11 (CL-11, CL-K1) is a MASP-1/3-associated 
plasma collectin with microbial-binding activity. J Immunol 
2010;185:6096–104.
24. Heja D, Kocsis A, Dobo J, Szilagyi K, Szasz R, Zavodszky P, et al. 
Revised mechanism of complement lectin-pathway activation 
revealing the role of serine protease MASP1 as the exclusive activa-
tor of MASP-2. Proc Natl Acad Sci USA 2012;109:10498–503.
25. Møller-Kristensen M, Thiel S, Sjöholm A, Matsushita M, 
Jensenius JC. Co-operation between MASP-1 and MASP-2 in 
the generation of C3 convertase through the MBL pathway. Int 
Immunol 2007;19:141–49.
26. Schwaeble WJ, Lynch NJ, Clark JE, Marber M, Samani NJ, 
Ali YM, et al. Targeting of mannan-binding lectin-associated 
serine protease-2 confers protection from myocardial and 
gastrointestinal ischemia/re-perfusion injury. Proc Natl Acad Sci 
USA 2011;108:7523–28.
27. Matsushita M, Fujita T. Cleavage of the third component of 
complement (C3) by mannose-binding-protein-associated serine 
protease (MASP) with subsequent complement activation. 
Immunobiology 1995;194:443–48.
28. Sekine H, Takahashi M, Iwaki D, Fukita T. The role of MASP-1/3 
in complement activation. Adv Exp Med Biol 2013;735:41–53.
29. Takahashi M, Ishida Y, Iwaki D, Kanno K, Suzuki T, Endo Y, et al. 
Essential role of mannose-binding lectin-associated serine 
protease-1 in activation of the complement factor D. J Exp Med 
2010;207:29–37.
30. Banda NK, Takahashi M, Levitt B, Glogowska M, Nicholas J, 
Takahashi K, et al. Essential role of complement mannose-
binding lectin-associated serine proteases-1/3 in the murine 
collagen antibody-induced model of inflammatory arthritis. 
J Immunol 2010;185:5598–606.
31. Degn SE, Jensenius JC, Thiel S. The pro-factor D cleaving activity 
of MASP-1/-3 is not required for alternative pathway function. 
J Immunol 2014;192:5447–8.
32. Takahashi M, Sekine H, Fujita T. Comment on “The pro-factor 
D cleaving activity of MASP-1/-3 is not required for alternative 
pathway function”. J Immunol 2014;192:5448–9.
33. Moghimi SM, Hunter AC, Murray JC. Long-circulating and 
target-specific nanoparticles; theory to practice. Pharmacol Rev 
2001;53:283–318.
34. Moghimi SM, Szebeni J. Stealth liposomes and nanoparticles: 
critical issues on protein-binding properties, activation of 
proteolytic blood cascades and intracellular fate. Prog Lipid Res 
2003;42:463–78.
35. Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R, 
et al. Rapid formation of plasma protein corona critically 
affects nanoparticle pathophysiology. Nat Nanotechnol 
2013;8:772–81.
36. Cedervall T, Lynch I, Lindman S, Berggard T, Thulin E, Nilsson H, 
et al. Understanding the nanoparticle-protein corona using 
methods to quantify exchange rates and affinities of proteins 
for nanoparticles. Proc Natl Acad Sci USA 2007;104:2050–5.
37. Gjelstrup LC, Kaspersen LD, Behrens MA, Pedersen JS, Thiel S, 
Kingshott P, et al. The role of nanometer-scaled ligand patterns 
in polyvalent binding by large mannan-binding lectin oligomers. 
J Immunol 2012;188:1292–306.
Brought to you by | University of Durham
Authenticated
Download Date | 6/21/16 5:31 PM
268      Moghimi et al.: Insidious pathogen-mimicking properties of nanoparticles
Bionotes
S. Moein Moghimi 
Nanomedicine Research Group and Centre 
for Pharmaceutical Nanotechnology and 
Nanotoxicology, Department of Pharmacy 
and NanoScience Centre, University of 
Copenhagen, Universitetsparken 2, DK-
2100 Copenhagen Ø, Denmark 
moien.moghimi@sund.ku.dk
S. Moein Moghimi read Biochemistry at the University of Manches-
ter (UK) and in 1989 earned his PhD in Biochemistry (Liposome 
Immunobiology) from Charing Cross Hospital Medical School 
(Imperial College, University of London). He is currently based at the 
University of Copenhagen (Denmark) where he serves as Professor 
of Nanomedicine at the Department of Pharmacy, Professor of Phar-
maceutical Nanotechology at the NanoScience Centre, and Director 
of the Centre for Pharmaceutical Nanotechnology and Nanotoxi-
ocology. He is also a full member and affiliate professor at the 
Department of Translational Imaging, Houston Methodist Research 
Institute (Weill Cornell Medical College), Houston Methodist Hospi-
tal Systems, Houston, Texas (USA), adjoint professor at the Depart-
ment of Pharmaceutical Sciences, Skaggs School of Pharmacy and 
Pharmaceutical Sciences, University of Colorado-Denver Medical 
Center (USA), visiting professor at University of Padova (Italy) and 
the elected Fellow of the Institute of Nanotechnology (UK). Earlier, 
he served as the Honorary Professor of Nanomedicine at the Mul-
tidisciplinary Research Center, Shantou University (China). Before 
joining Copenhagen, Moein was Senior Lecturer in Biopharmacy and 
Molecular Pharmaceutics at the School of Pharmacy, University of 
Brighton (UK) and The University Research Fellow in Advanced Drug 
Delivery Systems at the Department of Pharmaceutical Sciences, 
University of Nottingham (UK). His research activities are focused 
on pharmaceutical nanoscience and fundamental nanomedicine and 
nanosafety. Moein is the Associate Editor of Nanomedicine: Nano-
technology, Biology and Medicine and the Journal of Biomedical 
Nanotechnology and further serves on the editorial board of several 
peer-reviewed international journals, including Advanced Drug 
Delivery Reviews, Nanomedicine-UK, Journal of Liposome Research 
and Molecular and Cellular Therapies.
Peter P. Wibroe  
 Nanomedicine Research Group and Centre 
for Pharmaceutical Nanotechnology and 
Nanotoxicology, Department of Pharmacy 
and NanoScience Centre, University of 
Copenhagen, Universitetsparken 2,  
DK-2100 Copenhagen Ø, Denmark
Peter P. Wibroe has a solid background at the interface of nano-
technology and pharmaceutical sciences. Peter is dedicating his 
research to the intriguing interplay between the physicochemical 
properties of synthetic nanoparticles and biological systems, 
with a special focus on the complement system. Peter is cur-
rently enrolled as a PhD student in the Nanomedicine Group led 
by Professor Moghimi, where he is developing immune-safe and 
efficient drug delivery vehicles based on understanding of the 
molecular mechanisms by which nanoparticle surface presentation 
modulates complement recognition and responses. In this respect, 
Peter has already published several papers and reviews about the 
complement system and the underlying mechanisms of material 
recognition.
Linping Wu 
Nanomedicine Research Group and Centre 
for Pharmaceutical Nanotechnology and 
Nanotoxicology, Department of Pharmacy 
and NanoScience Centre, University of 
Copenhagen, Universitetsparken 2,  
DK-2100 Copenhagen Ø, Denmark
Linping WU obtained a Master’s degree in Biomaterials from 
Shantou University (China) in 2008. He began his PhD studies under 
the direction of Professor Moghimi at the University of Copenhagen 
and obtained his PhD in Nanomedicine in 2014. Currently he is a 
senior postdoctoral scientist in the same group, focusing on design 
and engineering of immune-safe advanced biomaterials and drug 
delivery systems for specific targeting through an interdisciplinary 
approach.
Z. Shadi Farhangrazi 
Biotrends International, Denver 
Technological Center, Greenwood Village, 
CO, USA
Z. Shadi Farhangrazi, PhD, MS, MBA is a biochemist, neuroscientist, 
infectious diseases expert, strategist, entrepreneur, and an expert 
in the area of innovation and entrepreneurship. She is the Founder, 
President and Managing Partner of management consulting firm 
Biotrends International. Farhangrazi is also a faculty member at 
Daniels College of Business, and University College, University of 
Denver. She has been teaching workshops and classes on entrepre-
neurship, innovation, strategy and non-profit management and has 
worked with multinational companies, SMEs, non-profit organiza-
tions and governmental organizations internationally. She has an 
active interest in nanomedicine innovation and translation.
Brought to you by | University of Durham
Authenticated
Download Date | 6/21/16 5:31 PM
